Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial

Our recent 48-week trial on chronic hepatitis B patients with multiple drug resistance who switched to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) showed ahigh rate of virologic response (VR). 1 Byun K.S. et al. Clin Gastroenterol Hepatol. 2022; 20: 427-437 e5 Abstract Full Text Full Text PDF PubMed Scopus (24) Google Scholar However, increases in body weight and cholesterol levels with TAF treatment were concerning. 2 Surial B. et al. Ann Intern Med. 2021; 174: 758-767 Crossref PubMed Scopus (53) Google Scholar , 3 Lim Y.S. et al. Aliment Pharmacol Ther. 2022; 55: 921-943 Crossref PubMed Scopus (8) Google Scholar , 4 Ogawa E. et al. Aliment Pharmacol Ther. 2022; 56: 713-722 Crossref PubMed Scopus (9) Google Scholar